1995 LDF Conference Abstract -- Vancouver, BC

Return to Conference Archive


8th Annual LDF International Scientific Conference on Lyme Borreliosis and other Spirochetal and Tick-borne Diseases:
with an emphasis on Mechanisms of Lyme Borreliosis Persistency

Abstracts of Presentations

John Millar, MD - Provincial Health Officer, British Columbia
Diane Kindree, BSN - Lyme Borreliosis Society of British Columbia
Martina H. Ziska, MD - Lyme Disease Foundation

Welcome and Opening Remarks

No abstract available


James Katzel, MD
Ukiah Valley Medical Center

Lyme Borreliosis Clinical Overview

No abstract available


James H. Oliver, Jr., PhD
Callaway Professor of Biology,
Director, Institute of Arthropodology and Parasitology
Georgia Southern University

Update on the Enzootiology of B. burgdorferi in the Southern US

We have isolated B. burgdorferi from cotton mice (Peromyscus gossypinus), cotton rats (Sigmodon hispidus), woodrats (Neotoma floridana) and the ticks Ixodes scapularis and Ixodes dentatus. Locations of isolates extend along the coast from Cape Canaveral , FL northward to the northern coasts of South Carolina and inland in central Georgia and southeast Missouri. Prevalence of B. burgdorferi in rodents may be quite high in some foci (75%). Currently it is unclear whether there are several separate parallel enzootic cycles operating or if there are weblike overlap among them. B. burgdorferi strains are more genetically heterogenous in the southern U.S. than those reported from the northern states. Infectivity varies among the isolates and one wonders if there are resulting differences in clinical symptoms and pathology produced in humans.


John F. Anderson, PhD
Director
The CT Agricultural Experiment Station

Ecology of Lyme Disease in Northeastern United States

Some of the highest incidence rates of Lyme disease (>200,000 cases/100,000 population/county) occur in Northeastern United States. The primary tick vector is Ixodes scapularis which is extremely abundant in many wooded and suburban areas where white-tailed deer are common. This tick has been recorded feeding on 120 different species of animals (birds, mammals, lizards). The causative-agent, Borrelia burgdorferi sensu stricto, has frequently been recovered from humans, Ixodes scapularis, and white-footed mice. Variants of the spirochete have been recovered from Ixodes scapularis, the rabbit associated tick Ixodes dentantus, and cottontail rabbit. Variants have not been recovered from humans, and therefore are not known to cause human disease. The interaction of the spirochete with its tick vector and wild host reservoirs will be discussed.


Satyendra Nath Banerjee, MD
Head, Vector-borne Diseases
British Columbia Centre for Disease Control

Isolation of Borrelia burgdorferi in British Columbia During 1992-1994
S.N. Banerjee, M. Banerjee, K. Fernando, M.Y. Dong, M. Altamirano and J.A. Smith. Provincial Laboratory, BC-CDC

The survey of ticks in B.C. during 1988 to 1991 was limited to adult ticks. In 1992 we began trapping rodents in 20 selected sites and juvenile ticks were retrieved from them. Tick guts as well as six organs from rodents, viz., ear, bladder, kidney, spleen, liver and heart were cultured in BSK II medium with antibiotics. All isolates were immunostained with Mab for P31, P34, P39 and P41 ag. SDS-PAGE profiles, PCR for OSPA gene and DNA sequence of 16SrRNA gene were analyzed for all axenic cultures. Up to 1991 when we had only adult ticks for culture, no spirochete was isolated 0/1360 (0%). In 1992 B. burgdorferi (Bb) was isolated from 1/539 (0.2%) ticks and 0/28 (0%) mice. In 1993 20/2086 (1%) ticks and 11/243 (4.5%) mice had Bb. In 1994, 7/691 (1%) ticks and 9/211 (4.1%) mice had Bb. SDS-PAGE protein profiles of isolates were comparable to that of Bb. All Bb were positive by Mab tests and by PCR for OSPA. DNA sequences of 16SrRNA gene were similar to Bb-B31. Bb was isolated from I. angustus and I. pacificus ticks. The presence of spirochetes in juvenile and adult ticks as well as in rodents suggests establishment of Bb in B.C. Our results show that culture of host organs and culture of juvenile ticks retrieved from hosts may be more successful than culture of adult ticks only.


Patricia Daly, MD, FRCPC
Associate Director, Epidemiology
B.C. Centre for Disease Control

Lyme Disease in British Columbia
Patricia Daly(1), Satyen Banerjee(2), Craig Stephen(1) (1) Communicable Disease Epidemiology Services, British Columbia Centre for Disease Control; (2) Provincial Laboratory, British Columbia Centre for Disease Control

In June, 1994, borreliosis was made a reportable disease under the Communicable Disease Regulations of the Health Act in the province of British Columbia. This action was taken because of several pieces of evidence. Since 1988, there have been several cases of clinically suspected Lyme disease with positive serology for Borrelia burgdorferi who appear to have acquired Lyme disease from within the province. At the same time, studies have identified the presence of tick species in British Columbia that are known to transmit B. burgdorferi. Further studies, which are ongoing, have revealed the presence of B. burgdorferi in several tick species form the southwest coastal regions of the province, as well as in deer mice hosts. The case definition to be used for reporting purposes is that developed by the Canadian consensus conference on Lyme disease in 1991 (CDWR 1991; 17(13):66). Based on the Canadian consensus conference guidelines, British Columbia is considered an endemic area for Lyme disease, although the geographical boundaries for endemicity have not been defined and will require further study.


Raj Gill, BSc
Health Science Officer, Provincial Laboratories
B.C. Centre for Disease Control

Lyme Disease Cases Acquired in British Columbia 1992-1994
Raj Gill, Satyendra Banerjee and Maya Banerjee

Research on Lyme borreliosis in British Columbia has been on going since 1986. Our first positive case was a 2 year old female from Burns Lake in 1988. Two patients were found to be positive in 1989; a 44 year old female from Salt Spring Island and a 71 year old female form Galiano Island. Only on 46 year old male was positive in 1992 from Kootenay Lake. In 1993, three cases were reported; one 58 year old female from Oliver, a 74 year old female from Nanaimo and a 66 year old male from Cortes Island. As of October 1994 4 cases have been confirmed; two males from Agassiz and Lumby and 2 females form Port Coquitlam and Port Moody. This makes a total of 11 cases of Lyme disease acquired in B.C. during 1988-1994 out of a total of 43 cases seen at the Provincial Laboratory, B.C.C.D.C. Only 2 cases showed the classical EM rash, most patients were febrile with headache, fatigue and muscle pain. Elderly patients presented with arthralgia and myalgia. All patients were positive by the ELISA method and confirmed by Western Blot sets and clinical diagnosis by physicians. It is pertinent to note that during 1993-94 Dr. S. Banerjee's Vector Borne Disease Laboratory isolated B. burgdorferi the etiologic agent from the deer mice Peromyscus maniculatus and two species of ticks viz. Ixodes pacificus and I. angustus collected from the places where cases were identified. On the basis of our findings and the Lyme disease consensus report on case definitions, B.C. should be considered an endemic area for Lyme disease.


Julie A. Rawlings, MPH
Texas Department of Health

Surveillance for Tick-borne Relapsing Fever in Texas Caverns

Tick-borne relapsing fever (TBRF) is caused by Borrelia spirochetes and is transmitted by Ornithodoros ticks. In Texas, the vector is O. turicata, found in caves frequented by sheep and goats or rodent and snake burrows; the agent is B. turicatae. Spelunkers may be at risk of acquiring TBRF as they explore Texas caves. In an attempt to establish the prevalence of exposure to B. turicatae in caverns, a questionnaire was administered to and sera was collected from 112 persons attending a Texas Speliological Society meeting in October, 1994. Data collected by questionnaire were analyzed to identify risk factors for disease were analyzed to identify risk factors for disease and evaluate histories of illness in these caverns. Each specimen was tested by indirect immunofluorescent antibody test (IFA) for antibody to three species of Borrelia. Eighteen were reactive.


Ron F. Schell, PhD
Professor and Chief Bacteriologist
Wisconsin School of Medicine

Introduction of Lyme Arthritis and Role for Borrelia burgdorferi Specific T-Lymphocytes
Lony C.L. Lim and Ronald F. Schell

We showed that severe destructive Lyme arthritis developed in vaccinated hamsters after challenge with isolates of Borrelia burgdorferi sensu lato and suggested a role for cell-mediated immunity. Specifically, severe destructive arthritis was readily evoked in immunocompetent inbred LSH hamsters vaccinated with a whole-cell preparation of Formalin-inactivated B. burgdorferi organisms in adjuvant when challenged with the homologous (vaccine) isolate before high levels of protective borreliacidal antibody developed. Once high levels of protective borreliacidal antibody developed, vaccinated hamsters were protected from homologous challenge and development of arthritis. Vaccinated hamsters, however, still developed severe destructive arthritis when challenged with other isolates of B. burgdorferi sensu lato. We now show that B. burgdorferi specific T-lymphocytes were responsible for the development of severe destructive arthritis. B. burgdorferi specific T-lymphocytes obtained from immunocompetent hamsters vaccinated with a whole-cell vaccine conferred on naive recipient hamsters the ability to develop severe destructive arthritis when challenged with B. burgdorferi sensu stricto isolates. The successful demonstration that B. burgdorferi T-lymphocytes were responsible for the adoptive transfer of severe destructive arthritis was confirmed by immunological enrichment for T-lymphocytes and characterization of the transferred cells. These studies are important for the development of a safe vaccine (whole or sub-unit) and for determining immunologic modulators to prevent the development of the signs and symptoms of Lyme arthritis.


Mario T. Philipp, PhD
Chairman, Department of Parasitology
Tulane Regional Primate Research Center

Efficacy of Recombinant OspA Vaccine Formulations in the Rhesus Monkey
Philipp M (1), Lobet Y (2), Robert D (1), Dennis V (1), Desmons P (2), Gu Y. (1), Hauser P (2), Lowrie Jr. R (1). (1) Tulane University Primate Res. Center, Louisiana, USA; (2) SmithKline Beecham Biologicals, Belgium

Three different vaccine formulations, NS1-OspA/aluminium hydroxide (Alum), NS1-OspA/Alum/MPL (an immunostimulant), lipidated OspA/Alum, and one placebo (Alum) were used in a vaccination trial involving 16 male 2-3-year-old Chinese Macaca mulatta (rhesus). Four animals were randomly assigned to each of 4 groups, and each group received one of the vaccine formulations. Three 10 µg doses of each vaccine were given to each animal intramuscularly into the cranial thigh, at 4-week intervals. All animals were exposed to the bite of Ixodes scapularis nymphs infected with the B31 strain of Borrelia burgdorferi (Bb), 5 weeks after the last injection. Of the 50 ticks that fed upon the animals in the placebo group, 48 contained spirochetes detectable by a direct fluorescence assay (DFA) with an anti-Bb polyclonal antibody, whereas only one of 130 ticks on the vaccinated animals had detectable Bb by DFA. On Western blots of whole Bb antigens, serum antibody from each of the control animals reacted with 10-16 antigens 4 weeks post-challenge (PC), and 22-36 by week 40. Vaccinated animals failed to develop any detectable anti-Bb antibodies during the same study period, except for the anti-OspA response induced by the vaccine. Skin biopsy and blood samples obtained weekly during the first 4 weeks PC from both control and vaccinated animals yielded no spirochetes upon in vitro culture. In contrast, skin samples from all of the control but none of the vaccinated animals contained Bb DNA during the first 4 weeks as revealed by PCR using primers that hybridize to a chromosomal DNA fragment of Bb.

In the same time period, 2/4 controls and 2/16 vaccinated animals had deep perivascular lymphocytic infiltrates in the skin adjacent to the infection site, with cells that stained positive with MAbs reacting with OspA and with a 7.5 kDa lipoprotein of Bb. Organs and tissues from several organ systems of the 4 controls and the 4 animals vaccinated with lipidated OspA and one of the animals vaccinated with NS1-OspA/MPL and with NS1-OspA were analyzed postmortem. No gross pathology was observed in any animals. In the control, unvaccinated animals, inflammation often accompanied by positive immunostaining with anti-7.5 kDa protein and anti-OspA MAbs, and by positive PCR was observed in the kidney (in 2 out of 4 animals), urether (2/4), heart (3/4), joints (1/4), nerves (4/4). In the vaccinated monkeys, no inflammation was observed in the kidneys, ureter and joints, while an inflammation milder than that seen in control animals was detected in the heart (2/6) and nerves (2/6). The lungs of 4/4 control animals and 5/6 vaccinated animals showed lymphocytic hyperplasia. Some macrophages within these cell clusters stained positive with the anti-7.5 and anti-OspA MAbs. PCR of lung tissue was positive for 2/4 control and 3/4 vaccinated animals.

The difference in the tick infection rate between ticks that fed on vaccinated and control monkeys, the lack of seroconversion in the vaccinated animals and the absence of spirochetal DNA in the skin of the vaccinated animals in the weeks following the challenge, indicate that the vaccinated monkeys were protected against the tick challenge. The post mortem analysis, however, suggests that a very low spirochete burden (non-immunogenic) or a transient infection may have occurred in some of the vaccinated animals. These last observation warrant further analyses of the remaining animals.


Alan Barbour, MD
Departments of Medicine and Microbiology
University of Texas Health Science Center

The Borrelia turicatae-mouse Model of Lyme Disease

Prevention of Lyme disease through vaccination is now seen as a reasonable and perhaps necessary strategy for control of infection in humans and domestic animals. The focus of vaccine development has been on OspA, an outer membrane protein of the species of Borrelia that causes Lyme disease in North America, Europe, and Asia. Studies in animals showed the effectiveness of recombinant OspA in protecting against syringe- and tick- delivered challenges. In the last two years human trials of OspA as a vaccine have begun. The progress in one set of these human trials of safety, immunogenicity, and efficacy will be presented. An additional emphasis will be on vaccine candidates in earlier stages of investigation.


Bettina Wilske, MD
Pettenkofer - Institute, Germany

Antigenic Variation of Borrelia burgdorferi sensu lato: Implications for Pathogenesis, Diagnosis, and Prophylaxis of Lyme Disease
B. Wilske, V. Preac-Mursic, V. Fingerle, S. Jauris-Heipke, D. Roosler, and G. Will, Pettenkofer Institute

Wild type strains of Borrelia burgdorferi sensu lato express OspA or OspC (or both) in abundant amounts. Expression of the two proteins is negatively correlated and appears to vary with the environment. Osp A is regularly expressed in Ixodes ricinus whereas OspC is rarely detected. Analysis of the human antibody response by Western blot suggest the inverse situation in the human host (strong expression of OspC, in contrast to low expression of OspA). Using a panel of OspA-specific monoclonal antibodies (MAbs) we previously classified European strains into seven OspA-serotypes (confirmed by sequence analysis) (1). Phenotypic analysis with OspC MAbs revealed at least 13 different types (2). OspC sequence analysis confirmed the immunological heterogeneity at a molecular level. In some strains (including also American strains) OspC was considerably heterogenous whereas OspA was highly conserved.

Analysis of a large number of European isolates from patients (n=102) revealed a significant association of the OspA-serotype with the clinical manifestation of the disease:

source type 1 type 2 type 3 type 4 type 5 type 6 type 7 total

CSF 8 5 3 12 3 10 2 43
skin 4 57 0 2 1 4 0 68

The high diversity of strains isolated from patients with neuroborreliosis (all seven serotypes were found) has important implications for microbiological diagnosis (serodiagnosis, PCR) as well as for vaccine development. (1) Wilske, B. et al., J. Clin. Microbiol.: 31 (1993) 340-350 (2) Wilske, B. et al., J. Clin. Microbiol. (1995), in press


David W. Dorward, PhD
Rocky Mountain Laboratories, NIAID
National Institutes of Health

Virulent Borrelia burgdorferi Specifically Attach to, Activate, and Kill TIB-215 Human B-lymphocytes
David W. Dorward and Elizabeth R. Fischer. NIH/Rocky Mountain Laboratories

In order to examine the effects of Lyme disease spirochetes on immune effector cells, experimental co-incubations of B. burgdorferi Sh-2-82 and cultured human and B- and T-lymphocytes, TIB-215 and H9 cells respectively, were begun in the fall of 1994. Comparisons were made in the structure and viability of B- and T-cells incubated with varying concentrations of virulent or attenuated B. burgdorferi, or virulent B. hermsii after 1, 24, 48 and 72 hr. The levels of IgM antibody secretion of B-cells exposed to spirochetes and /or the known B-cell activators IL-5 and IL-6 were also compared. Examination by light and electron microscopy showed that at relative concentrations of 100:1, low passage B. burgdorferi attach rapidly to 90=% of B-cells. Video microscopy revealed that initial attachment involved spirochetal apices. Within one hour, affected B-cells began to aggregate in culture wells. After 24 hours, numerous spirochetes covered B-cell surfaces, and up to 50% of B-cells were lysed. Such effects were dependent on infectious dose. No significant attachment and killing was noted in co-incubations involving high passage B. burgdorferi, virulent B. hermsii, or T-cells. Furthermore, heat killed or sonicated spirochetes, or spirochetal culture supernatants had no apparent effects on B-cells, suggesting that attachment and cytolysis require inducible factors. Since there was no evidence of B-cell invasion, and cytolysis was serum complement-independent, B-cell killing may involve a previously undocumented toxigenesis. Electrophoretic and western blot analysis, using convalescent human Lyme disease serum, showed that at least four proteins and human immunogens were produced by virulent spirochetes in response to co-incubation with this B-cell line. Whether any or all of these factors are involved in B-cell killing remains to be determined. Quantitative comparisons of IgM secretion by B-cells, incubated with spirochetes and/or interleukins 5 and 6, showed that all three spirochetal populations effectively activated the B-cells and stimulated IgM secretion. Such activation is consistent with previous studies with normal human B-cells. These studies document that B. burgdorferi exhibits specific cytopathic effects on cultured B-cells, and provide a model for examining the possibility that such interactions between spirochetes and B-cells may play a role in colonization and persistence of B. burgdorferi in mammals.


Alan Barbour, MD
Departments of Medicine and Microbiology
University of Texas Health Science Center

The Borrelia turicatae - Mouse Model of Lyme Disease

Mice infected with Borrelia burgdorferi develop arthritis and carditis, in common with humans with Lyme disease. However, mice and other non-primate animal models of B. burgdorferi infection only transiently or inconsistently have involvement of the central nervous system. We have found that a strain of B. turicatae, an agent in relapsing fever in southwestern North America, produces infection and involvement of both peripheral and central nervous system of mice. In addition, the neurotropism of this species appears to be limited to certain serotypes. Serotype A notably infects the brain, but serotype B does. In contrast serotype B infections are characterized by a severe polyarticular arthritis; serotype A produces only mild arthritis. The only discernible difference between serotype A and B of B. turicatae is in an outer membrane protein that is homologous to OspC proteins of B. burgdorferi. These findings suggest that disease manifestations of Lyme disease and other borrelial infections are in part determined by features of an infecting organism.


Manuel Altamirano, MD
Clinical Assistant Professor, University of British Columbia

DNA Sequences of 16S RNA of B. burgdorferi Isolates from Canada and U.S.A.
M. Altamirano, S. Banerjee, M. Banerjee, K. Fernando, M. Dong and G. McDonald-Jones; Provincial Laboratories, British Columbia Centre for Disease Control; Vancouver General Hospital; Pathology and Laboratory Medicine, University of British Columbia

The phylogenetic relationship between some of the Borrelia isolates form Canada and U.S.A. has been investigated by amplification of a 276 base pairs segment of the 16S RNA gene. The DNA sequences were compared with those analyzed for B. burgdorferi B31 and other groups such as B. hermsii, B. anserina and B. garinii. Primers for the Polymerase Chain Reaction (PCR) were selected from conserved regions of the gene that codes for the 16S RNA in Borrelia strains. DNA extracted from isolates was amplified by PCR in a 50 ul reaction for 35 cycles, using 48¡ C for annealing temperature. The PCR products were purified by HPLC and both strands were sequenced using florescent labeled primers in cycling reactions in the presence of Thermus thermophylus DNA Polymerase. The sequencing reaction were analyzed in the automatic laser DNA sequencer. The 16S RNA sequences from the Canadian isolates were clustered and similar to B. burgdorferi B31 strain. Differences in sequences were seen in some isolates previously identified as B. burgdorferi. The phylogenetic relationships of those isolates along with further molecular biology studies shall be discussed.


Judit Miklossy, MD
Division of Neuropathology
University Institute of Pathology, Switzerland

Further Evidences for a Spirochetal Etiology of Alzheimer's Disease

Recently we reported that spirochetes were found by dark field microscopy in the blood, cerebrospinal fluid and were isolated form the brain tissue of Alzheimer's disease (AD) cases, including two familial AD cases. Moreover the spirochetes were cultured from the cortex tissue in three out of four AD cases investigated. Reference strains of spirochetes showed a positive immunoreaction with a monoclonal antibody against the § amyloid precursor protein (APP) of AD, indicating that spirochetes may contain APP or at least an APP-like (APLP) protein. Using scanning and atomic force microscopy we observed that the isolated and cultured microorganisms from the AD brain possess axial filament. Using a monoclonal antibody against Borrelia burgdorferi we found a positive immunoreaction in senile plaques and in neurons in the brain of a patient with concurrent AD and Lyme disease. Individual spirochetes free in the neuropil were also observed. The 4',6-diamidine-2-phenylindole dihydrochloride (DAPI) Which binds selectively to DNA is frequently used for the visualization of the bacterial DNA of Mycoplasma in cell cultures. We expected that DAPI would also bind to the DNA of spirochetes. If AD is caused by spirochetes, consequently in addition to resident cell nuclei we would find DNA also in senile plaques, neurofibrillary tangles and in the neuropil threads. Indeed when stained with DAPI reference spirochetes may be visualized, but also senile plaques, neurofibrillary tangles and neuropil threads in AD exhibit fluorescence which can be abolished be DNAase pretreatment. Further investigations demonstrated some similar histochemical properties of reference spirochetes and those of the AD type histological changes. These observations seem to reinforce the hypothesis that AD may correspond to the tertiary stage of neurospirochetosis.


Willy Burgdorfer, PhD
Rocky Mountain Laboratories
National Institutes of Health

Is "Coll/Ag-30" the Answer to Lyme Borreliosis and other Infectious Diseases?

This presentation relates to the recent announcement by Dr. M. Paul Farber of his forthcoming book "Coll/Ag-30 (Mild Silver Protein) the Silver Bullet" considered by the author to be the answer to numerous infectious diseases including Lyme disease, AIDS, multiple sclerosis and candida infections.

Colloidal silver preparations have commonly been used as a successful broad-spectrum antimicrobial agent against at least 650 different diseases during the early part of this century. However, because of high costs, this colloidal silver therapy became obsolete with the advent of the less expensive antibiotics.

In his struggle to overcome and recover from the debilitating clinical manifestations of late Lyme disease and from a serious candida yeast infection as a result of prolonged treatment with antibiotics, as well as from early symptoms of multiple sclerosis, Dr. Farber conducted an extensive literature research and rediscovered the claim of Colloidal Silver as an effective treatment from microbial diseases.

Treating himself with a recently developed and less expensive version of Mild colloidal silver (Coll/Ag-30), Dr. Farber claims to have fully recovered from his illnesses. Dr. Farber's Coll/Ag-30 therapy and its results in several pioneering patients on Coll/Ag-30 are presented.


Claude F. Garon, PhD
Chief, RML Microscopy Branch
National Institute of Allergy and Infectious Disease
Rocky Mountain Laboratories

Borrelia burgdorferi's Subsurface DNA Network Represents a Possible Target for a New Category of Antimicrobial Agent

The total DNA content of a number of B. burgdorferi isolates from around the world has been characterized. These assays have revealed a collection of both linear and circular molecules ranging in size form two to one thousand kilobasepairs. In addition, the relative number of copies of these molecules appears to be tightly controlled. In contrast to some microbial extrachromosomal elements which are replicated autonomously and are present in hundreds, if not thousands, of copies for each chromosome, the number of individual DNA molecules seen in B. burgdorferi does not appear to vary over many generations of culture. Since important genes have been mapped to the chromosome, and to both linear and circular plasmids, this linkage control mechanism appears to be important and may be exploited using new biochemical agents which target DNA replication. B. burgdorferi cells grown in the presence of radioactively labeled 5-bromo-2-deoxy-uridine readily incorporated label into both linear and circular DNA molecules of all sizes and at a roughly similar rates. Cis-platinum staining of spirochetes followed by high resolution backscattered electron detection located nucleic acid molecules in blebs and over the entire inner surface of the spirochete membrane. A gentle, en bloc DNA purification procedure visually confirmed the presence of a nucleic acid network containing both linear and circular molecules. The network contained radioactive DNA precursor label, could be stained with specific nucleic acid stains, and could be disrupted with both DNAase and proteinase by not RNAase treatments. However with the exception of trioxalen crosslinking, B. burgdorferi seemed relatively insensitive to known eukaryotic and prokaryotic DNA replication inhibitors.


Dagmar Hul’nsk‡, RNDr, PhD
WHO Collaborating Center for Lyme Borreliosis,
National Institute of Public Health, Czech Republic

Cellular Infection of Human Fibroblasts, Langerhans Cells, and Leukocytes by Liquor and Blood Isolates of B. garinii and B. afzelii with Emphasis to Antibiotic and Antibodies Treatment

The present study of the uptake of B. garinii strains M92, MI92, K24 and B. afzelii strains Kc90 and HII8 by fibroblasts and Langerhans cells revealed that Borreliae were internalized by both conventional and by coiling phagocytosis after 24 hr. Leukocytes phagocyted borreliae more quickly, after 10-30 min. Spirochetes wrapped up by coiled pseudopodes which created transmembrane channels were protected against antibiotic and antibodies treatment. Spirochetes engulfed by conventional phagocytosis of leukocytes were altered after 60-120 min and ionized the phagosomes of fibroblasts after 48 hr. High and low passage B. garinii and B. afzelii opsonized with antibodies against OspA formed blebs and vesicles which were associated with cultured eukaryotic cells. Borrelial vesicles were endocyted by fibroblasts Which were associated with cultured eukaryotic cells. Borrelial vesicles were endocyted by fibroblasts after 10-30 min. Prior vesicle-fibroblasts association influenced father engulfment of B. garinii by conventional but not by coiling phagocytosis after 24 hr. Vesicles, isolated experimentally by differential centrifugation and filtration of BSK cultures were internalized inside the endocytic vesicles of fibroblasts after 30 min. The low passage B. garinii strain possessed OspA and OspB proteins at molecular weight of 32 kDa and 35 kDa. Complement with surface proteins of low passage strains had a cytotoxic effect on fibroblasts after 3-6 hr. The liquor isolate M92 was negative for OspA protein but after father coculturing with fibroblasts the strain changed phenotype and developed OspA protein after two week.


Sam T. Donta, MD
Professor of Medicine
Boston University Medical Center

Evidence for an Intracellular Reservoir for Lyme Borreliae

The mechanisms responsible for relapsing symptoms in patients with Lyme disease remain to be delineated. The organism can only rarely be found following the initial infection and dissemination. In examples of other infectious diseases characterized by recurring or persistent infection, the reservoir of microorganisms is intracellular. These include viruses (e.g. herpes, hepatitis B/C), parasites (e.g. malaria, leishmania), and fungi (e.g. histoplasma). Whether other fungi (e.g. cryptococci, pneumocystis) remain dormant inside cells or on their surfaces is unclear. Some bacteria persist in endosomes at a neutral pH (e.g. chlamydia, legionella) whereas others (e.g. M. tuberculosis) can survive in endolysosomes. Where T. pallidum survives is unknown. Tissue culture models of intracellular infection by B. burgdorferi have been described; in the fibroblast model, ceftriaxone was ineffective against intracellular borreliae, data consistent with the poor intracellular penetration of betalactam antibiotics from the results of clinical studies, beta lactams have been less effective than would be predicted from their in vitro activities. Tetracycline has been a generally effective agent. The macrolides have been less effective than would be predicted by their in vitro activities and their intracellular penetration, suggesting that the Lyme borreliae persist in endolysosomal-like vesicles at an acidic pH. The addition of the lysosomotropic agent hydroxychloroquine to macrolide therapy results in generally successful treatment outcomes.


Benjamin J. Luft, MD
SUNY at Stony Brook School of Medicine

Use of Recombinant, Chimeric Proteins for the Diagnosis of Lyme Disease
B.J. Luft, R.J. Dattwyler, Department of Medicine, SUNY Stony Brook. B.J. Johnson, Centers for Disease Control, B.C. McGrath, J.J. Dunn, Biology Department, Brookhaven National Laboratory.

Lyme disease is a multisystem disorder whose etiologic agents are spirochetes of the genus Borrelia. The ability to detect Lyme borreliosis early in the disease has been hindered by the unavailability of a fast, and accurate diagnostic test. Currently, a need exists for a sensitive and specific diagnostics that can detect a wide array of naturally occurring antigenic variants of Borrelia.

In this study we have developed recombinant, chimeric antigens which provide reactivity to serum samples obtained from Lyme disease patients. The chimeric proteins containing peptides from OspA, OspB, OspC, p 41 and P 93 were prepared, and then tested as antigen against sera obtained from patients at various stages of Lyme disease. The results indicated that at least two of these chimeric proteins were effective in detecting serum antibodies against Borrelia. These studies demonstrate the feasibility of a specific, broad-spectrum diagnostic test for Lyme disease based upon a recombinant multivalent antigen.


Mark M. Manak, PhD
Sr. Vice President
Biotech Research Laboratories

Detection of B. burgdorferi Sequences in Clinical Specimens by a PCR Capture Assay M. Manak (1), I. Gonzalez-Villase–or (1), K. Wu (1), S. Crush-Stanton (1), and R.C. Tilton (2) (1) Biotech Research Laboratories, (2) Boston Biomedica/North American Laboratory Group

A simplified PCR-based DNA format developed for the direct detection of B. burgdorferi nucleic acid sequences in blood, urine and other biological fluids to aid in the diagnosis of Lyme disease. Conserved sequences in the OspA gene were labeled with biotin and used as primers for PCR amplification of DNA extracted from clinical specimens. The resulting biotin labeled products were captured in microtiter plates by specific hybridization with internal sequences of these products. Detection was accomplished by streptavidin conjugated peroxidase followed by colorimetric detection of the enzyme substrate. As few as 3-10 copies of B . burgdorferi DNA could be detected. We have examined a total of 1200 specimens representing over 350 patients suspected of Lyme disease. The vast majority of specimens tested were negative by PCR and had no serological markers indicative of Borrelia infections. Positive results were found in 87 specimens representing urine, blood, serum, joint fluid and CSF samples. The results to date suggest that whole blood or serum specimens are a more reliable indicator of active infection than is urine. Although the majority (89%) of patients with positive PCR results were also positive for serological markers (WB, ELISA, IgM Capture), a significant number of patients were positive by OspA gene sequences in clinical samples and promises to be a valuable adjunct to the current serological diagnostic tests to help control Lyme disease infections.


Bruno Schmidt, MD
Dipl.Ing.Dr., LBI for Dermato-Venerological Serodiagnosis, KH Lainz

Detection of Borrelia burgdorferi-DNA in Urine from Patients with Lyme Borreliosis
B.L. Schmidt, Ch. Wagner, E. Aberer, A. Luger

Direct demonstration of Borrelia burgdorferi (Bb) by culture is not a rapid method and a high sensitivity can only be obtained by taking skin biopsies as specimen. In order to improve detection, different PCR-methods (high cycle, nested- and heminested, drop in/drop out) were developed and compared on different genes. The most sensitive and specific assay was based on a simple preparation of Bb-DNA out of human urine and a new nested PCR using a specific part of the flagellin gene as target.

Up to now more than eight hundred patients with various clinical manifestations of Lyme borreliosis (mostly dermatological) have been examined. As an example, results of 90 erythema migrans (EM) patients are presented: PCR was reactive in 80 patients (88.9%). In comparison, serology was reactive for IgG in 11.1% to 16.7% of patients using tests with a B. garinii antigen. Only 2 out of 66 tested sera had antibodies to the p39 antigen. Specific IgM could be detected in 25, 6%-40, 5% of the patients depending on the different tests used.

In conclusion, detection of Bb in EM-patients can be improved dramatically by examining urine for presence of Bb-DNA.


Richard C. Tilton, PhD
North American Laboratory Group

A Solid-phase Enzyme-linked Immunosorbent Antigen Detection for Lyme Disease Diagnosis
C.C. Tai (1), M. Manak (1), H. Weissberger (1), T. Patamawenu (1), and R.C. Tilton ( 2) (1) Biotech Research Laboratories, (2) Boston Biomedica/North American Laboratory Group

An enzyme-linked immunosorbent assay system was developed for the detection of antigens of Borrelia burgdorferi in urine and other body fluids form patients suspected of having Lyme disease. A species-specific rabbit antiserum against OspA, OspB, and OspC was used for both capture and detection of Borrelia antigens in samples. F(a,b)2 fragments of purified IgG from the antiserum were coated on polystyrene microtiter plate. Test samples were added directly to the wells without concentration. Following incubation at room temperature and the removal of unreacted reagents, antigens adsorbed to the plate were detected by IgG from the same rabbit antiserum. The immuno-reactivity on the plate was amplified by a protein A-biotin/streptavidin-HRP reporting system. Color generated by the enzyme-substrate reaction was read at 450 nm. All reagents used in the assay were optimized by cross titrations against crude cell protein and also against cultured cells, serially diluted in normal human urine. Standard curves were constructed for both the antigen and intact cells using data obtained from the above titrations, respectively. The optimized assay system was shown to have an efficient detecting range of 10-200 ng of crude cell protein, and as little as 100-200 cultured cells of B. burgdorferi, in the presence of a detergent. The performance of this assay was validated by testing confirmed clinical specimens from patients with or without infection by B. burgdorferi.


Steven Schutzer, MD
Division of Allergy and Immunology
University of Medicine and Dentistry of NJ - NJ Medical School

The Immune Response and its Application toward Diagnosis

The immune response to an infectious agent involves complex interaction among T helper and suppressor cells, macrophages, and B cells. The B cells which differentiate into antibody producing cells first produce IgM, then IgG, then IgA to the antigenic components of the agent. Initially, and in certain other instances, the predominance of the antibody may be found bound to the agent in an antigen-antibody or immune complex.

Serologic diagnosis of infection with the spirochete Borrelia burgdorferi (Bb), the cause of Lyme disease has been hampered by the variability among existing tests as well as the prolonged time needed for the humoral response to reach thresholds of detection by conventional assays. As specific antibody (Ab) made be found bound to an infectious agent, especially early in the infection, and during active infection, we hypothesized that this could be occurring in Lyme disease. We isolated and dissociated serum immune complexes from Lyme disease patients, fulfilling modified CDC criteria, and controls. Immune complexes were first collected by polyethylene glycol (PEG). Following dissociation by high pH, the dissociated constituents were analyzed by ELISA and Western blots. Specificity of the reactive Ab was evaluated by probing for the target antigen using monoclonal and polyclonal Abs, as well as recombinant proteins.

Complexed Ab to Bb was found in 10 of 11 very early cases(p=2 x 10E-7), 55 of 56 (p= or less than 10E-3) symptomatic patients with Lyme disease, 0 of 50 healthy controls, 2 of 50 patients from the endemic areas with other diseases including those likely to have elevated levels of immune complexes, 13 of 13 (p= or less than E-8) persistently seronegative patients who had erythema migrans and a subset of 4 of 4 who were also positive on a T cell proliferative assay to Bb, and 0 of 8 patients who had recovered. In the early acute cases complexed IgM was the first antibody to be detected. Predictive values (PV), based upon a sensitivity of 98% and a specificity of 98% were PV+ of 36% (prevalence of 1%) to 98.6% (prevalence of 50%) and PV- of 99.9% to 99.7% between these prevalences.

The data suggest that this relatively simple technique has potential to support or exclude a clinical diagnosis of early as well as active Lyme disease.


Patricia K. Coyle, MD
Department of Neurology
Suny at Stony Brook School of Medicine

New tools in the Diagnosis of Neurologic Lyme Disease

The diagnosis of neurologic Lyme disease has been hampered by the lack of reliable and available active infection assays. New tools are becoming available with regard to analysis of cerebrospinal fluid (CSF), as well as use of new test modalities, to help define Borrelia burgdorferi- related neurologic syndromes.

CSF diagnostic tests include spirochete culture; detection of Borrelial antigens or DNA; and detection of specific IgM antibodies, complexed antibodies, or intrathecal antibody production. Although specificity of all these tests is high, sensitivity for neurologic Lyme disease varies greatly depending on the syndrome and timing of infection.

This paper will discuss the current status of these tests in different neurologic syndromes attributed to Lyme disease. Other diagnostic tools include evaluation of brain blood flow deficits by SPECT, and of cognitive processing and hearing deficits by evoked potential testing. Neuropsychologic test which evaluate reaction time, attention, and learning/retrieval of verbal memory appear to be preferentially affected. These new tools should help refine the diagnosis as well as the optimal management of neurologic Lyme disease.


Alan B. McDonald, MD
Pathology Department
St. Elizabeth's Hospital

Morphologic Heterogeneity of Borrelia burgdorferi

Detection of B. burgdorferi in tissue specimens is prima faciea evidence of Lyme borreliosis. Recovery of Borrelia burgdorferi from in vitro cultures is equivalent to direct visualization of the pathogen in tissue specimens. All other laboratory diagnostic modalities (routine serology, Western blot, PCR, antigen capture) are easier to obtain from reference laboratories. The morphologic diversity of the spirochete in tissue sections is mow well established from the published work of European and American investigators; and the wide range of "legitimate" spirochetal form for B. burgdorferi is mirrored by the plethora of morphologic variants of T. pallidum which were published by Warthin and Starry, Coutts & Coutts, Delammater, Ovcinnikov, Rose and Morton, and J. L. Smith in their classical pathologic tissue studies of syphilitic tissues.

The original discovery by Burgdorfer of the spirochetal etiology of Lyme borreliosis was predicated on the astute observation in a Giemsa stained preparation of a cytology smear from the intestinal tract of an Ixodid tick. Dr. Burgdorfer recognized that wavy threadlike profiles (which were not corkscrew shaped profiles) were spirochete profiles.

Fewer that five board certified histopathologists have published papers on the morphology of B. burgdorferi in tissues. The experience of these workers will be the subject of this presentation.


Craig Cleveland, MD
East Hyde Park Internal Medicine

Poster Session

No abstracts availble


Edward Masters, MD
Family Physicians Group Inc.

Clinical Presentations of Borreliosis in the Lower Midwest

This presentation focuses on clinical Lyme disease in the Midwest. Examples of erythema migrans along with serological and histological findings are presented. Potential tick vectors are discussed, especially the association of Amblyomma americanum (lone star) ticks with erythema migrans. Examples of late sequelae are presented along with comparisons to other geographic areas. Clinical differentiation of the erythema migrans rash from the brown recluse spider bite is elucidated. Also presented are other clinical and epidemiologic findings associated with clinical Lyme disease.


George Price, MD
Clinical Associate Professor, Division of Rheumatology
University of British Columbia

Lyme Arthritis in British Columbia, Canada

G.E. Price and S.N. Bannerjee; Seymour Medical Clinic and Provincial Laboratory, BC-CDC The first known locally acquired case of Lyme arthritis in B.C. is described. The patient had frequent tick exposure where he lived, on a forested island on the south coast of the province. The diagnosis was established by a compatible clinical picture of arthritis, and multiple bands on IgG and IgM Western blot analysis. The arthritis, which had been intermittent for more than six months, responded quickly to treatment with doxycycline with no recurrence after two years.


Bruce McManus, MD, PhD
Chairman, Pathology and Laboratory Medicine
St. Paul's Hospital
University of British Columbia

Cardiovascular Manifestations of Lyme Disease

Cardiac abnormalities in association with acute or chronic borreliosis have been described since the late 1970's and worldwide there have been about 200 such patients reported. A high frequency of electrophysiological perturbations has been documented, with a prominence of third degree atrioventricular block and, less commonly, second and first degree block. Perimyocarditis and clinical heart failure are seen in about 15% of patients with evident heart involvement. Diagnosis of cardiac disease in patients with Lyme disease depends on a degree of suspicion when other symptoms and signs of borreliosis (especially neurological changes) are present and when the patient exhibits presyncope, syncope, palpitations, shortness of breath, chest pain, and electrocardiographic abnormalities. The endomyocardial biopsy may be helpful in the diagnosis of Lyme carditis, and the organism of cause may be stained (with silver), cultured, and/or detected by molecular means. The use of anti-myosin or gallium scanning and magnetic resonance imaging in the assessment of patients with Lyme carditis has recently been suggested.

Therapy for cardiac involvement by Lyme disease includes a general strategy of antibiotics, and the expectation that a temporary pacemaker may be valuable (one-third of patients) during the acute inflammatory phase, when heart block is common. anti-inflammatory drugs, steroidal and nonsteroidal, have been used in therapeutic regimens. Outcome of Lyme carditis is generally very favorable with about 95% of patients apparently having full functional recovery. Thus, permanent pacemakers are typically not required. Only a rare report has raised the possibility of chronic heart muscle disease secondary to Lyme carditis, while no particular relationship between serological results and chronicity of cardiac disease has been defined. Rare fatalities have been attributed to cardiac involvement by Lyme disease. Opportunities to define the pathological and pathobiological nature of Lyme carditis should be emphasized to clarify the manner in which the offending organisms and the immune responses participate in injury of the heart muscle and what factors may induce or facilitate chronic cardiac dysfunction.


Ernie Murakami, MD
Clinical Associate Professor
University of British Columbia Medical School

Lyme Disease Case in the Lower Mainland, and a New Wood Tick Removal Technique
Ernie Murakami, MD, Department of Family Practice, UBC; Nima Shojamia, Medical Student, UBC; Satyen N. Banerjee, PhD, Provincial Laboratory, BC-CDC

A 57 year old man presented to the medical clinic at an Agassiz Correctional Institute in B.C. on April 18, 1994. Complaining of a circular rash on his right leg, neck stiffness and right shoulder chronicum migrans was the diagnosis and serologically Lyme disease was confirmed. Since this patient was incarcerated for three years the local animal vector had to be present at the Agassiz Institution, (rats, mice, cats and raccoons). Erythromycin was given to this patient and he improved clinically. Wood ticks carry disease (second only to mosquitoes) to man and animals: i.e. Rocky Mountain spotted fever, Colorado tick fever, tularemia, babesiosis and Lyme disease. Pediatric abstract summarized five popular methods of removal: jelly, nail polish, alcohol, hot match, forceps and fingers (Pediatric, volume 74, June 1985). All these above method may cause increased intraabdominal pressure thus host infection possibilities are greatly increased. The method proposed for the removal involves the injection of Xylocaine intradermally and the hydrostatic pressure causes the tick to fall off the host voluntarily. In some cases a sharp needle or scalpel is required for extraction. This method avoids and prevents any regurgitation of insect abdominal contents. The wood tick is complete and alive for speciation and culturing for infective agents.

This technique has been practiced in Hope, B.C. for the past five years by myself and my associates. All research for this project was done in Hope, B.C.


Rudolph J. Scrimenti, MD
Medical College of Wisconsin

Acrodermatitis Chronica Atrophicans

ACA, the first manifestation of LB to be described, is an outstanding example of prolonged latency and chronic infection. It is rarely reported in America. Our knowledge is drawn from a rich European experience. It consists of an early inflammatory stage and a late atrophic stage. A poorly demarcated acral erythema or edema usually ushers in the disease. It disseminates primarily to other acral sites often sparing the torso. Juxta articular modules and fibrotic linear bands may develop over the extensor surfaces of the extremities. Over many months to many yeast, atrophy may develop. Eventually, lymphadenopathy, weight loss, fatigue, neuropathies, phalangeal joint luxations may appear. Sclerotic and atrophic lesions, indistinguishable clinically and histopathologically from morphea and lichen sclerosus atrophicans (LSA) may be seen. Histopathology reveals a predominant CD4 lymphocytic infiltrate, lymphatic telengiectasis and lymphedema. With progression, atrophy of the skin and elastic fibers develops. A rich admixture of plasma cells, if present may distinguish sclerotic and atrophic ACA from morphea and LSA et A. in the absence of the spirochete. Many lymphocytes and keratinocytes express HLA-DR and HLA-DQ antigens which disappear with therapy. Bb specific IgG titers are usually high. Doxycycline is the usual therapy for uncomplicated ACA. Benzyl penicillin IV and oral doxycycline is the preferred therapy if neurologic and/or arthritic complications are present.


Irwin T. Vanderhoof, PhD, CLU - New York University - Stern School of Business
R. C. Smithson, PhD - Lockhead Palo Alto Research laboratory

Symptoms and Characteristics of Chronic Lyme Disease Patients

Over the years the Lyme Disease Foundation and the Society of Actuaries have compiled a data base of symptoms, characteristics, and treatment of over 1,000 Lyme disease patients. The data is based upon a questionnaire filled out by the members of the studied group. Since the participants were self selected it is not surprising that the group is primarily composed of patients with long standing illness - the chronic cases.

The analysis is of two types. The first is the calculation of the descriptive statistics of the group. These include symptoms, test results, geographic locations, and cure or continuing impairment. Cost of treatment information is also studied and an attempt is made to correlate this with the other dimensions of the data.

The second type of analysis is the use of a probabilistic neural network technique developed at Lockheed to try to find a pattern for those patients that have continuing illness as opposed to those who are eventually symptom free.


Julian E. Davies, PhD
Professor and Head, Department of Microbiology & Immunology
University of British Columbia

Antibiotic Resistance in Spirochetes

The Gram-negative spirochetes are a diverse group of bacteria with a broad ecological distribution. The diseases caused by spirochetes are usually treated with antibiotics or antibiotic combinations. There have been very few reports of antibiotic resistance developing during clinical treatment.

Antibiotic prophylaxis is often used, which may increase the possibility of emergence of antibiotic resistant strains. If recently history is any guide, the problem of antibiotic resistance in bacteria is usually considered after the fact. The review of biochemical mechanisms of antibiotic resistance and their dissemination among bacteria will be reviewed and indication of relevance of these mechanisms to spirochetes will be given.


Kenneth B. Liegner, MD
New York Medical College

Spectrum of Antibiotic-Responsive Meningoencephalomyelitides

Two cases of chronic Lyme meingoencephalomyelitis (CMEM), one culture-proven initially seronegative case with spastic paraparesis and cranial nerve dysfunction and the other initial seronegative ultimately fatal case of CMEM with massive hydrocephalus shown to be OspA antigen positive in the cerebrospinal fluid followed by a skin eruption centered about the bite site evolved to CMEM negative for bb by all available diagnostic methodologies, yet which responded both clinical and as shown by progressive improvement of abnormal parameters on serial CSF examination, to an 8 month course of daily intravenous (I.V.) cefotaxime (CFOTX). A fourth case of CMEM meeting clinical and CSF diagnostic criteria for multiple sclerosis (MS) and also lacking any laboratory support of the diagnosis of Lyme disease (LD) but with considerable epidemiologic risk for LD, showed clear improvement both clinical and in abnormal CSF parameters in response to 4 month of daily I.V. CFOTX. Conclusion: Potential responsiveness of CMEM to intensive antibiotic treatment is not excluded by inability to prove a diagnosis of CNS borrelial disease with presently available methods, regardless of whether standard of research assays are utilized. A randomized trial of intensive intravenous antibiotic treatment of MS patients should be considered.


Joseph J. Burrascano, Jr., MD
Southampton Hospital

Management of Chronic Lyme Disease

The management of patients with chronic Lyme disease can be challenging. Not enough is known about the pathophysiology of this condition, why patients' presentations differ, and why response to treatment is so variable. In addition, tests do not exist that allow us to establish the diagnosis or follow the outcome of our interventions with absolute accuracy.

The approach to treatment of chronic Lyme begins with the assessment of whether prior antibiotic treatments were adequate. It is truly a myth that a patient with disseminated disease is cured with four weeks of antibiotic therapy. There are now over one dozen literature reports documenting failure of this approach, which is not surprising in light of the unscientific and arbitrary nature of this recommendation. Mechanisms of resistance of B. burgdorferi to eradication in the human include biologic properties of this organism such as latency and S-layers, presence of Bb in privileged sites such as in intracellular and intraocular locations, inadequate understanding of antibiotic pharmacology in killing this germ and in the common practice of ignoring basic, well understood pharmacological principles such as half lives, tissue and cell penetration and serum, CSF and tissue levels. If treatment was not optimal, then a more aggressive approach is indicated, in terms of both dose and duration.

Any time oral antibiotics are used, serum peak and trough levels should be documented whenever possible, for my studies have shown, for example, an unexplained 100 fold variability in serum ampicillin levels in patients matched by age, body size and drug dose. Intramuscular benzathine penicillin has been shown to be unexpectedly effective, as has intravenous but not oral doxycycline in the chronic patient. Intravenous antibiotics offer huge potential advantages in efficacy compared to oral regimens, and newer methods of administration, such as interrupted and pulse dosings have made such medications safer and more effective in this setting.

If the patient has received what would appear to be adequate treatment and still has not responded, then the diagnosis must be reassessed, and any other concurrent conditions present must be identified and corrected, such as superinfections, nutritional inadequacies, and subtle immune deficiencies. It is crucial to find out whether steroids or other immunosuppressives were given during the course of the infection, as such medications can have a negative impact on the patients ultimate therapeutic outcome. My studies have shown that many patients with resistant infections have deficiencies in B, T, and/or killer cell function. If these abnormalities can be corrected then treatment response improves.


James H. Katzel, MD
Ukiah Valley Medical Center

Diagnosis and Treatment of Disseminated Lyme Disease

Recognizing disseminated Lyme disease (LD) is paramount to successful treatment outcome, since each stage of the disease requires a different treatment strategy.

The latent period is either observed clinically or treated with prophylactic antibiotics.

Early localized infection is treated with anti-spirochetal antibiotics for 3-4 weeks or until the erythema migrans (EM) is eradicated.

Disseminated disease...

...requires a much more aggressive approach to both diagnosis and treatment. These patients are ill and often appear septic, although only a few days from the time of the infecting tick bite. Antibiotics are needed at higher doses and for longer periods of time to fully eradicate the widely disseminated spirochetal infection, and to restore the patient's feeling of clinical well being. Intravenous antibiotics are used for Lyme meningitis, children with central neurologic problems and pregnant patients. However, the vast majority are successfully treated with longer term oral anti-spirochetal antibiotic regimens. The distinction must be made, between patients with a single EM lesion and no flu like illness, and those patients with more than one EM lesion and/or a systemic flu like illness. The latter group respond better to aggressive early treatment and usually avoid chronic persistent disease.


Brian A Fallon, MD
Director, Lyme Disease Program; Assistant Professor
Columbia University and NYS Psychiatric Institute

Persistent Lyme Encephalopathy: To-Treat or Not-to-Treat?
Brian A. Fallon, MD, N. Weiss MA, A. Goldstein BA, Mr Liebowitz MD. The NYS Psychiatric Institute

Problems with fatigue, memory, attention, depression, and mental disorganization are central features of Lyme encephalopathy (LE). When faced with a LE patient who has already received months of antibiotics and 6-12 weeks of IV antibiotics, clinicians must ask several questions. First, is the diagnosis of LE correct? Second, are there other comorbid disorders that could be treated better (e.g., depression, panic disorder, ADD)? Third, are somatoform features involved (e.g., psychogenic seizures)? Fourth what has been the course of antibiotic treatment and response. Clinical data will be presented to support this approach as well as research data from an ongoing study of the efficacy of repeated courses of IV antibiotics among patients with persistent L.E. In this naturalistic pilot study of LE patients who have received no more than 16 weeks of prior IV antibiotics, patients are tested at baseline and 4 months later using standardized measures of memory, intelligence, attention, psychomotor performance, depression, anxiety, and disability. Preliminary findings, contrasting patients who did receive more IV antibiotics to patients who did receive more IV antibiotics to patients who did not, will be discussed.


Joseph J. Burrascano, Jr., MD
Southampton Hospital

Public Forum

Public forum free for residents of British Columbia. All scientific presenters are present to answer questions from the public.


About the LDF
Updates
Awards
Donations
Volunteer
Diseases
Ticks
Scientific Education
Community Education
Childrens Corner
Education Materials
Journal
Research
Picture Gallery
Faces of Lyme Disease
Resources
Legislative
Online
Media
Vaccines
Disclaimer